- Prescribing Advice for GPs - https://www.prescriber.org.uk -

Pimecrolimus Safety Letter

The manufacturer of Pimecrolimus (Elidel®) has written to healthcare professionals regarding rare reports of cancers in patients using pimecrolimus. Based on current data, the letter states, "a causal link can neither be confirmed nor refuted."

The letter reiterates the EMEA recommendations made earlier this year, reported here. It recommends that:

Action: Clinicians should be aware of these recommendations and ensure they are being followed.